Begin typing your search...

Glenmark to market COVID treatment spray SaNOtize in India, other Asian markets

image for illustrative purpose

Glenmark Pharma inks licensing agreement to commercialize its innovative nasal spray Ryaltris
X

2 Aug 2021 12:30 PM IST

Drug firm Glenmark Pharmaceuticals on Monday said it has signed an agreement with Canadia's biotech firm SaNOtize Research and Development Corp to commercialise its Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Glenmark Pharmaceuticals and SaNOtize Research and Development Corp announced an exclusive long term strategic partnership to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS)in Asian markets including India, Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor Leste and Vietnam, Glenmark said in a regulatory filing.

"The committee has recommended a phase III clinical trial to be conducted in Indian patients in the weeks to follow. The phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand name FabiSpray in India, by fourth quarter of the calendar year 2021," the company added.

Glenmark Covid-19 SaNOtize India Asia 
Next Story
Share it